Neuberger Berman Group
BMRN icon

Neuberger Berman Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Neuberger Berman Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,899
Closed -$957K – 2058
2025
Q1 		$957K Buy
2,899
+675
+30% +$45.4K ﹤0.01% 1330
2024
Q4 		$662K Buy
+2,224
New +$149K ﹤0.01% 1441

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Neuberger Berman Group's BMRN Position: Q2 2026 in Review

Neuberger Berman Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 57% in Q2 2026, selling an estimated $1.17M and leaving 16,196 shares worth $927K. The position accounts for ﹤0.01% of the portfolio, ranked #1554.

Neuberger Berman Group first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $126M in Q3 2018. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Neuberger Berman Group held 16,196 shares of BioMarin Pharmaceuticals worth $927K as of Q2 2026.
  • Neuberger Berman Group sold 21,273 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.17M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1554 holding.
  • Neuberger Berman Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Neuberger Berman Group's BioMarin Pharmaceuticals position peaked at $126M in Q3 2018.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.